BeStock  
Stocks › Biotechnology › PTGX

Protagonist Therapeutics PTGX

US equityMarket cap rank #1605Biotechnology
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$274.41M+5,723.6% YoY
Operating profit$218.33M+570.3% YoY
Net profit$220.02M+659.3% YoY
Diluted EPS$3.07+595.2% YoY
Free cash flow-$23.46M-1,058.4% YoY
Operating cash flow-$23.22M

Revenue, last 8 quarters

$170.6MDec '24$28.3MMar '25$5.5MJun '25$4.7MSep '25$7.4MDec '25$56.4MMar '26$213.5MJun '26$274.4MSep '26

Net profit, last 8 quarters

$131.7MDec '24$-11.7MMar '25$-34.8MJun '25$-39.3MSep '25$-44.4MDec '25$3.8MMar '26$162.8MJun '26$220.0MSep '26

Diluted EPS by quarter

1.98Dec '24-0.19Mar '25-0.55Jun '25-0.62Sep '25-0.69Dec '250.05Mar '262.29Jun '263.07Sep '26

Free cash flow by quarter

$-29.5MDec '24$124.8MMar '25$-29.6MJun '25$-2.0MSep '25$-37.1MDec '25$-49.2MMar '26$218.9MJun '26$-23.5MSep '26

Annual revenue

$28.6MFY20$27.4MFY21$26.6MFY22$60.0MFY23$434.4MFY24$46.0MFY25

Profitability & balance sheet

Gross margin99.6%
Operating margin58.6%
Net margin62.0%
Return on equity39.6%
Return on assets37.0%
Return on invested capital36.1%
Current ratio19.85
Liabilities / assets5.4%
Cash & investments$800.06M
Total debt$6.18M
Net cash (debt)$793.89M
Free cash flow / sales19.8%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $274.41M $213.48M $56.37M $46.02M $7.44M
Total Operating Revenue $274.41M $213.48M $56.37M $46.02M $7.44M
Cost of Revenue $1.10M – – – –
Gross Profit $273.31M – – – –
Operating Expense $54.98M $54.71M $60.02M $204.14M $57.79M
Selling and Admin Expenses $13.70M $12.65M $13.28M $44.85M $11.43M
-General & Admin Expense $13.70M $12.65M $13.28M $44.85M $11.43M
Research & Development $41.27M $42.06M $46.74M $159.29M $46.36M
Operating Profit $218.33M $158.77M -$3.65M -$158.13M -$50.36M
Net Non-Operating Interest Income (Expense) $8.25M $6.43M $5.88M $28.79M $6.76M
Non-Operating Interest Income $8.25M $6.43M $5.88M $28.79M $6.76M
Other Income (Expense) -$14,000.00 -$81,000.00 $53,000.00 $27,000.00 -$124,000.00
Other Non-Operating Income (Expenses) -$14,000.00 -$81,000.00 $53,000.00 $27,000.00 -$124,000.00
Pretax Profit $226.57M $165.11M $2.28M -$129.31M -$43.72M
Tax $6.56M $2.27M -$1.50M $838,000.00 $666,000.00
Net Profit $220.02M $162.85M $3.78M -$130.15M -$44.38M
Profit from Continuing Operations $220.02M $162.85M $3.78M -$130.15M -$44.38M
Net Income to Parent Company $220.02M $162.85M $3.78M -$130.15M -$44.38M
Net Income to Common Stockholders $220.02M $162.85M $3.78M -$130.15M -$44.38M
Basic EPS $3.32 $2.47 $0.06 -$2.05 -$0.69
Diluted EPS $3.07 $2.29 $0.05 -$2.05 -$0.69

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.15B $885.54M $697.46M $668.19M $668.19M
Total Current Assets $1.10B $807.15M $613.46M $577.57M $577.57M
Cash and Cash Equivalents & Short-Term Investments $800.06M $782.58M $547.79M $567.36M $567.36M
-Cash and Cash Equivalents $498.30M $420.08M $193.71M $128.39M $128.39M
-Short Term Investments $301.77M $362.50M $354.07M $438.97M $438.97M
Receivables $290.91M $19.64M $57.12M $4.50M $4.50M
-Accrued Interest Receivable $3.12M $2.86M $3.46M $4.37M $4.37M
-Due from Related Parties Current $283.79M $13.42M $53.66M $121,000.00 $121,000.00
-Other Receivables $4.01M $3.37M – $10,000.00 $10,000.00
Prepaid Assets $3.96M $2.62M $3.99M $5.71M $5.71M
Other Current Assets $6.12M $2.31M $4.56M – –
Total Non-Current Assets $45.49M $78.40M $84.00M $90.61M $90.61M
Net PPE $9.82M $10.40M $11.17M $11.69M $11.69M
-Gross PPE $19.34M $19.52M $19.89M $20.00M $20.00M
-Accumulated Depreciation -$9.53M -$9.12M -$8.72M -$8.32M -$8.32M
Investments and Advances $34.56M $66.88M $72.55M $78.64M $78.64M
-Available for Sale Securities $34.56M – – – –
Other Non-Current Assets $1.12M $1.12M $288,000.00 $287,000.00 $287,000.00
Total Liabilities $61.64M $44.00M $41.99M $53.48M $53.48M
Total Current Liabilities $55.46M $37.18M $34.55M $45.44M $45.44M
Payables $10.72M $3.63M $8.94M $5.52M $5.52M
-Accounts Payable $5.92M $3.46M $8.44M $5.34M $5.34M
-Total Tax Payable $4.22M – – $0.00 $0.00
-Other Payable $577,000.00 $175,000.00 $502,000.00 $185,000.00 $185,000.00
Current Accrued Expenses $14.73M $15.85M $12.76M $15.32M $15.32M
Short-Term Debt and Capital Lease Obligation $2.45M $2.40M $2.34M $2.28M $2.28M
-Current Capital Lease Obligation $2.45M $2.40M $2.34M $2.28M $2.28M
Current Deferred Liabilities $16.31M $9.66M $6.28M $9.55M $9.55M
Total Non-Current Liabilities $6.18M $6.82M $7.44M $8.04M $8.04M
Long Term Debt and Capital Lease Obligation $6.18M $6.82M $7.44M $8.04M $8.04M
-Long Term Capital Lease Obligation $6.18M $6.82M $7.44M $8.04M $8.04M
Total Equity $1.08B $841.54M $655.47M $614.71M $614.71M
Stockholders' Equity $1.08B $841.54M $655.47M $614.71M $614.71M
Capital Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Common Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.18B $1.15B $1.12B $1.08B $1.08B
Retained Earnings -$84.02M -$304.04M -$466.89M -$470.67M -$470.67M
Less: Treasury Stock -$5.79M – – – –
Gains/Losses Not Affecting Retained Earnings -$1.30M -$828,000.00 -$269,000.00 $641,000.00 $641,000.00
Non-Current Deferred Liabilities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$23.22M $219.05M -$48.94M $57.67M -$36.98M
Net cash flow from continuing operations -$23.22M $219.05M -$48.94M $57.67M -$36.98M
Net Income from Continuing Operations $220.02M $162.85M $3.78M -$130.15M -$44.38M
Depreciation & Depletion & Amortization $409,000.00 $397,000.00 $407,000.00 $1.28M $376,000.00
Other Non-Cash Items $450,000.00 $440,000.00 $439,000.00 $1.58M $333,000.00
Change in Working Capital -$257.37M $42.37M -$67.06M $146.21M -$2.67M
-Change in Receivables -$271.01M $36.88M -$53.54M $164.88M $462,000.00
-Change in Prepaid Assets -$403,000.00 $4.22M -$1.92M -$2.36M -$365,000.00
-Change in Payables and Accrued Expense $7.98M -$710,000.00 -$7.79M $5.61M $5.10M
-Change in Other Current Assets $0.00 – – – –
-Change in Other Current Liabilities -$585,000.00 -$560,000.00 -$547,000.00 -$903,000.00 -$426,000.00
-Change In Other Working Capital $6.65M $3.38M -$3.27M -$21.02M -$7.44M
Net cash flow from investing $93.43M -$2.43M $90.89M -$49.33M $48.82M
Net Cash Flow from Continuing Investing Activities $93.43M -$2.43M $90.89M -$49.33M $48.82M
Net PPE Purchase and Sale -$237,000.00 -$168,000.00 -$215,000.00 -$1.59M -$144,000.00
Net Investment Purchase and Sale $93.67M -$2.26M $91.11M -$47.74M $48.96M
Financing Cash Flow $8.01M $9.74M $23.37M $22.86M $2.84M
Net Cash Flow from Continuing Financing Activities $8.01M $9.74M $23.37M $22.86M $2.84M
Proceeds from Stock Option Exercised $13.80M $9.74M $23.37M $23.34M $2.84M
Ending Cash Balance $498.59M $420.37M $194.00M $128.68M $128.68M
Net Change in Cash $78.22M $226.37M $65.32M $31.20M $14.68M
Beginning Cash Balance $420.37M $194.00M $128.68M $97.47M $114.00M
Free Cash Flow -$23.46M $218.88M -$49.16M $56.08M -$37.12M
Gain/Loss from Continuing Operations – – -$2,000.00 – –
Net Common Stock Issuance – – – $0.00 $0.00
Net Other Financing Charges – – – -$479,000.00 $0.00

Discussion

No comments yet — be the first to weigh in on PTGX.

Sign in to join the discussion.

Scroll to Top